Other Biomarkers in UC

Biomarkers in urine or exfoliated cells isolated from urine may be used to diagnose and monitor recurrence of UC.1 FDA-approved tests are available for detecting some of these biomarkers.1,2

 

NCCN recommendations

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendation

 

Only monitor for disease recurrence using FDA-approved urinary biomarkers for either3:

 

Chromosomal alterations by fluorescence in situ hybridization

NMP22 


According to NCCN Guidelines®, testing for
urinary biomarkers to detect cancer during
follow-up is optional.3


According to NCCN Guidelines®, testing for urinary biomarkers to detect cancer during follow-up is optional.3

FDA, Food and Drug Administration; NCCN, National Comprehensive Cancer Network; NMP, nuclear matrix protein; UC, urothelial carcinoma.

 

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

 

References: 1. Kamat AM et al. Eur Urol. 2013;63(1):4-15. 2. Hall MC et al. J Urol. 2007;178(6)‍‍2314-2330. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V5.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed September 27, 2018. To view the most recent and complete version of the guidelines, go online to NCCN.org.

Biomarkers for detection

Biomarkers for detection

 

Biomarkers for Detection

 

Biomarkers and commercially available tests for detecting UC1,2

Biomarker Sample type
FDA-approved test
  • Bladder tumor antigens
  • Voided urine
  • BTA-stat®, BTA-TRAK™
  • NMP22
  • Voided urine
  • NMP22® BladderChek®
  • Chromosomal alterations (chromosomes 3, 7, 17, and 9p21)
  • Voided urine/exfoliated cells
  • UroVysion Bladder Cancer Kit
  • Carcinoembryonic antigen, 2 bladder tumor cell-associated mucins
  • Voided urine/exfoliated cells
  • ImmunoCyt™
  • NMP BLCA-4
  • Voided urine
  • Not available
  • Survivin
  • Voided urine
  • Not available
  • Cytokeratins 8 and 18
  • Voided urine
  • Not available
  • Hyaluronic acid
  • Voided urine
  • Not available
  • Murine monoclonal antibody DD23
  • Exfoliated cells
  • Not available

BLCA-4, bladder cancer marker 4; BTA, bladder tumor antigen; FDA, Food and Drug Administration; NMP, nuclear matrix protein; UC, urothelial carcinoma.

 

References: 1.Kamat AM et al. Eur Urol. 2013;63(1):4-15. 2. Hall MC et al. J Urol. 2007;178(6):2314-2330.

Biomarkers for Detection

Biomarkers and commercially available tests for detecting UC1,2

Bladder tumor antigens

Sample type FDA-approved test
Voided urine

BTA-stat®,

BTA-TRAK™

NMP22

Sample type FDA-approved test
Voided urine

NMP22® BladderChek®

Chromosomal alterations (chromosomes 3, 7, 17, and 9p21)

Sample type FDA-approved test
Voided urine/exfoliated cells

UroVysion Bladder Cancer Kit

Carcinoembryonic antigen, 2 bladder tumor cell–associated mucins

Sample type FDA-approved test
Voided urine/exfoliated cells

ImmunoCyt™

NMP BLCA-4

Sample type FDA-approved test
Voided urine

Not available

Survivin

Sample type FDA-approved test
Voided urine

Not available

Cytokeratins 8 and 18

Sample type FDA-approved test
Voided urine

Not available

Hyaluronic acid

Sample type FDA-approved test
Voided urine

Not available

Murine monoclonal antibody DD23

Sample type FDA-approved test
Exfoliated cells

Not available

BLCA-4, bladder cancer marker 4; BTA, bladder tumor antigen; FDA, Food and Drug Administration; NMP, nuclear matrix protein; UC, urothelial carcinoma.

 

References: 1. Kamat AM et al. Eur Urol. 2013;63(1):4-15. 2. Hall MC et al. J Urol. 2007;178(6):2314-2330.